However, in cognitively normal subjects, APOE4 is not always associated with an increased risk of cognitive deterioration, suggesting that APOE4 effects on structural and/or clinical progression only become evident in mild cognitive impairment (MCI) and AD (Haller et al., 2017). This evidence concerns the gene APOE and Alzheimer disease.